Rani Therapeutics Holdings annual stock-based compensation
2020
2021
2022
2023
2024
2025
Rani Therapeutics Holdings Stock-Based Compensation Growth & History (RANI)
Rani Therapeutics Holdings's stock-based compensation was $11.8M for fiscal 2025.
View full Rani Therapeutics Holdings company overviewRani Therapeutics Holdings annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $11.8M | −$4.2M | −26.41% |
| 2024 | 2024-12-31 | $16.0M | −$3.0M | −15.66% |
| 2023 | 2023-12-31 | $19.0M | $3.2M | +20.44% |
| 2022 | 2022-12-31 | $15.8M | −$6.8M | −30.15% |
| 2021 | 2021-12-31 | $22.6M | $22.6M | — |
| 2020 | 2020-12-31 | $0 | — | — |
Rani Therapeutics Holdings quarterly stock-based compensation
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.4M | −$868,000 | −26.37% |
| Q1 2026 | 2026-03-31 | $2.1M | −$1.8M | −46.90% |
| Q4 2025 | 2025-12-31 | $2.2M | −$1.8M | −43.92% |
| Q3 2025 | 2025-09-30 | $2.3M | −$1.7M | −42.02% |
| Q2 2025 | 2025-06-30 | $3.3M | −$837,000 | −20.27% |
| Q1 2025 | 2025-03-31 | $3.9M | $55,000 | +1.42% |
| Q4 2024 | 2024-12-31 | $4.0M | −$495,000 | −11.03% |
| Q3 2024 | 2024-09-30 | $4.0M | −$925,000 | −18.63% |
| Q2 2024 | 2024-06-30 | $4.1M | −$1.0M | −19.68% |
| Q1 2024 | 2024-03-31 | $3.9M | −$545,000 | −12.34% |
| Q4 2023 | 2023-12-31 | $4.5M | −$13,000 | −0.29% |
| Q3 2023 | 2023-09-30 | $5.0M | $564,000 | +12.81% |
| Q2 2023 | 2023-06-30 | $5.1M | $1.2M | +29.30% |
| Q1 2023 | 2023-03-31 | $4.4M | $1.5M | +51.98% |
| Q4 2022 | 2022-12-31 | $4.5M | $1.3M | +42.19% |
| Q3 2022 | 2022-09-30 | $4.4M | −$14.3M | −76.45% |
| Q2 2022 | 2022-06-30 | $4.0M | $3.7M | +1309.93% |
| Q1 2022 | 2022-03-31 | $2.9M | $2.5M | +541.28% |
| Q4 2021 | 2021-12-31 | $3.2M | — | — |
| Q3 2021 | 2021-09-30 | $18.7M | $18.7M | — |
| Q2 2021 | 2021-06-30 | $282,000 | $282,000 | — |
| Q1 2021 | 2021-03-31 | $453,000 | — | — |
| Q3 2020 | 2020-09-30 | $0 | — | — |
| Q2 2020 | 2020-06-30 | $0 | — | — |
Rani Therapeutics Holdings stock-based compensation trends
Over the last five fiscal years, Rani Therapeutics Holdings's stock-based compensation increased from $0 to $11.8M, a change of $11.8M. The latest reported quarter, Q2 2026, shows $2.4M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Rani Therapeutics Holdings source filings ↗